Single Biggest Cancer Dictionary in the World

What is anti-CCR8 monoclonal antibody BAY3375968?

Pronunciation: /ˈænˌti ccr* eɪt ˌmɑnəˈkloʊnəl ˈæntɪˌbɑdi beɪ θri ˈmɪljən, θri ˈhənərd ənd ˈsɛvəntiˌfaɪv ˈθaʊzənd, naɪn ˈhənərd ənd sixty-eight*/

anti-CCR8 monoclonal antibody BAY3375968

Definition

A human immunoglobulin G1 (IgG1) afucosylated monoclonal antibody against C-C-chemokine receptor 8 (CCR8), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CCR8 monoclonal antibody BAY3375968 targets, binds to and blocks the activity of CCR8 on CCR8-positive tumor-infiltrating regulatory T cells (Tregs) in the tumor microenvironment (TME) and prevents chemokine ligand 1 (CCL1)-CCR8-mediated signaling. BAY3375968 eliminates CCR8-positive Tregs via the induction of Fc-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP), thereby depleting CCR8-positive Tregs. This may reactivate antitumor immune responses. CCR8 is specifically expressed on activated tumor-infiltrating Tregs in multiple types of cancer and plays a key role in immunosuppression. High expression is correlated with poor prognosis.